Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by various directors and executives on April 12, 2012. These acquisitions resulted from the reinvestment of dividends paid on shares held in the GlaxoSmithKline ShareReward Plan. The purchase price was 1403.9264 pence per Ordinary Share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of specific share purchases under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Dividend reinvestment via the ShareReward Plan.
- Transaction Date: April 12, 2012.
- Share Price: 1403.9264 pence per Ordinary Share.
- Participants: Includes Sir Andrew Witty (35 shares), Mr S M Bicknell (56 shares), Mr S Dingemans (4 shares), Mr E J Gray (56 shares), Mr S A Hussain (10 shares), Dr D Pulman (17 shares), Mr D S Redfern (56 shares), Ms C Thomas (56 shares), Mr P C Thomson (23 shares), Dr P J T Vallance (26 shares), and Mrs V A Whyte (33 shares).
- Notification Date: April 13, 2012.